Quarterly Cash Flow Report Appendix 4C
Filed with ASX · · 5 pages · English
Story so far
Earlier from Biotron
- Quarterly Activities Report
- $1.56M R&D Rebate Received
- BIT225 Effectiveness Against COVID-19 in Animals
- Quarterly Appendix 4C Cash Flow Report
- Biotron drug effective against COVID-19 in animals
Later from Biotron
- BIT225 effective against established SARS-CoV-2 in animals
- Positive FDA guidance for COVID-19 clinical program
- BIT225 Phase 2 HIV-1 Clinical Trial Fully Recruited
- Bit225 Covid-19 Human Study Commenced
- Second BIT225 Phase 2 HIV-1 Clinical Trial Fully Recruited
Follow Biotron into a list and get an email when it puts out news.
Follow Biotron